DEF: NeuroPace, Inc. Announces Annual Stockholders Meeting to Elect Directors and Ratify Accounting Firm

NeuroPace, Inc. will hold its Annual Meeting of Stockholders virtually on June 6, 2025, to elect directors and ratify the selection of PricewaterhouseCoopers LLP as its independent accounting firm.

Summary

• NeuroPace, Inc. is holding its Annual Meeting of Stockholders on June 6, 2025, virtually.
• The meeting will include the election of Joel Becker and Frank Fischer as Class I directors, each to hold office until the 2028 Annual Meeting.
• Stockholders will also vote to ratify the selection of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting 'For' the election of the director nominees and 'For' the ratification of the accounting firm selection.
• Only stockholders of record as of April 9, 2025, are entitled to vote.
• The company intends to mail the Notice of Internet Availability of Proxy Materials on or about April 22, 2025.
• The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting.

Sentiment

Score: 7

Explanation: The document is neutral in tone, focusing on procedural matters related to the annual meeting. The information is presented clearly and professionally, suggesting a stable and well-managed company.

Positives

• The Board of Directors is actively engaged in corporate governance, with regular meetings and committees overseeing key areas such as audit, compensation, and nominations.
• The company has a Code of Business Conduct and Ethics in place, promoting ethical behavior among officers, directors, and employees.
• The Audit Committee has reviewed the audited financial statements for the fiscal year ended December 31, 2024, and recommended their inclusion in the Annual Report on Form 10-K.
• The company provides indemnification for its directors and officers, protecting them from undue personal liability.

Negatives

• There were some late filings of Section 16(a) reports by executive officers due to administrative errors.

Risks

• The risk management oversight is spread across the Board and its committees, but specific details on the effectiveness of these processes are not provided.
• The company's success depends on attracting and retaining qualified personnel, and changes in key personnel could impact performance.
• The company operates in a competitive industry and faces risks related to market conditions, regulatory changes, and technological advancements.

Future Outlook

The document does not contain specific forward-looking statements regarding financial performance or business strategy beyond the routine matters of the annual meeting.

Management Comments

• The Board of Directors believes that the separation of the offices of the Chairperson and Chief Executive Officer is appropriate at this time because it allows our Chief Executive Officer to focus primarily on our business strategy, operations and corporate vision, while allowing our Chairperson to lead our Board of Directors in its fundamental role of providing advice to and oversight of members of management.

Industry Context

The company operates in the medical device industry, which is characterized by innovation, regulation, and competition. The election of directors with experience in this sector and the selection of a reputable accounting firm are standard practices for maintaining investor confidence and ensuring compliance.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is generally in line with industry standards for publicly traded medical device companies.
• The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm is a common practice among publicly traded companies, as it provides credibility and assurance to investors.
• The corporate governance practices, such as having independent directors and committees, align with best practices recommended by regulatory bodies and institutional investors.

Related Party Transactions

• On February 13, 2025, the company repurchased 5,270,845 shares of its common stock from KCK Ltd. for $49.5 million, at a price of $9.40 per share.

Stakeholder Impact

• Shareholders are asked to vote on key proposals, influencing the direction and oversight of the company.
• Employees are indirectly affected by the decisions made at the annual meeting, as they impact the overall governance and strategy of the company.
• Customers and suppliers may experience indirect effects based on the strategic direction set by the elected directors and ratified accounting firm.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 6, 2025.
• The company will file a Form 8-K to report the final voting results of the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Accounting Firm Ratification, Corporate Governance, NeuroPace